series-a
Stage
2
Investors
About
AirNexis Therapeutics is developing a Phase 2 dual PDE3/4 inhibitor (AN01) for the treatment of chronic obstructive pulmonary disease (COPD).
Explore AirNexis Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.